163 related articles for article (PubMed ID: 20944132)
1. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
[TBL] [Abstract][Full Text] [Related]
2. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
7. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
8. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases.
Nos C; Harding-MacKean C; Fréneaux P; Trie A; Falcou MC; Sastre-Garau X; Clough KB
Br J Surg; 2003 Nov; 90(11):1354-60. PubMed ID: 14598414
[TBL] [Abstract][Full Text] [Related]
9. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer.
Ajisaka H; Yonemura Y; Miwa K
Hepatogastroenterology; 2004; 51(57):900-5. PubMed ID: 15143943
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
11. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
Barranger E; Coutant C; Flahault A; Delpech Y; Darai E; Uzan S
Breast Cancer Res Treat; 2005 May; 91(2):113-9. PubMed ID: 15868438
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
13. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
15. [Very slight chance of other metastases in axillary nodes of breast cancer patients with a small sentinel node metastasis without extranodal tumor growth].
van der Loo EM; Hop WC; Tervoort MA; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(19):938-43. PubMed ID: 15160561
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between lymph node metastasis and the expressions of E-cadherin, N-cadherin, and matrix metalloproteinase in breast carcinoma].
Wang LH; Liu DY; Chen YJ; Hou L; Wang B; Mao LM; Lu S
Ai Zheng; 2002 Sep; 21(9):965-9. PubMed ID: 12508543
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors.
McKenna GJ; Meneghetti A; Chen YL; Mui AL; Ong C; Scudamore CH; McMaster WR; Owen DA; Chung SW
J Surg Oncol; 2005 Jun; 90(4):239-46. PubMed ID: 15906368
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases.
Xie M; Sun Y; Li Y
Laryngoscope; 2004 Dec; 114(12):2243-8. PubMed ID: 15564854
[TBL] [Abstract][Full Text] [Related]
20. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
